To evaluate the feasibility, safety, oncological outcomes and immune effect of neoadjuvant stereotactic radiation (Neo-SAbR) followed by radical nephrectomy and thrombectomy (RN-IVCT).
These are results from the safety lead-in portion of a single arm phase I-II trial.